CinCor Pharma

Rank#4302

Market Cap1.27B

CountryUnited States

Summary

CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. The company was incorporated in 2018 and is based in Waltham, Massachusetts.

History

CinCor Pharma was formed in August 2005 and is located in the San Francisco Bay area. The company was founded by Dr. Stephen G. Keneally and Thomas Miller, who had met while at Millennium Pharmaceuticals in 2000.

Mission

CinCor Pharma's mission is to discover, develop and commercialize life-saving treatments to address unmet medical needs and improve patients’ lives.

Vision

CinCor Pharma’s vision is to be the leader in the discovery and development of innovative drug treatments and technologies to significantly improve the lives of patients.

References

https://in.investing.com/equities/cincor-pharma

https://www.comparably.com/companies/vision/mission

https://www.crunchbase.com/organization/cincor-pharma

https://finance.yahoo.com/quote/CINC/

https://www.cincor.com

https://sec.report/CIK/0001868734

Leadership team

Mr. Marc M. P. de Garidel (CEO & Director)

Dr. Mason W. Freeman M.D. (Chief Medical Officer)

Ms. Catherine Pearce DHSc, M.B.A., MBA (Co-Founder & COO)

Products / Services